Skip to content

Effects of Subanesthetic-Dose Esketamine Combined with Oxycodone on Catheter-Related Bladder Discomfort (CRBD) in Patients Undergoing Transurethral Surgery: A Randomized Controlled Trial

Effects of Subanesthetic-Dose Esketamine Combined with Oxycodone on Catheter-Related Bladder Discomfort (CRBD) in Patients Undergoing Transurethral Surgery: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600131779
Enrollment
Unknown
Registered
2026-09-06
Start date
2026-09-08
Completion date
Unknown
Last updated
2026-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Catheter-related bladder discomfort (CRBD)

Interventions

Esketamine combined with oxycodone group:Esketamine combined with oxycodone

Sponsors

Tianjin First Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age >= 18 years; 2.American Society of Anesthesiologists (ASA) physical status I–III; 3.Scheduled for elective transurethral surgery; 4.Voluntarily provided written informed consent;

Exclusion criteria

Exclusion criteria: 1.Preoperative indwelling urinary catheter; 2.Pre-existing overactive bladder, urinary tract infection, neurogenic bladder, or other related conditions; 3.Long-term use of sedatives, analgesics, or psychotropic drugs; 4.History of schizophrenia, epilepsy, Parkinson's disease, myasthenia gravis, or intracranial hypertension; 5.History of opioid or ketamine abuse; 6.Severe hepatic or renal insufficiency (Child-Pugh class C, eGFR < 30 ml/min); 7.Severe cardiovascular and cerebrovascular diseases (e.g., unstable angina, myocardial infarction within the past 6 months, severe heart failure with EF < 40%); 8.Pre-existing hyperthyroidism, pheochromocytoma, or other relevant conditions; 9.Any other conditions deemed unsuitable for participation by the investigator or attending physician;

Design outcomes

Primary

MeasureTime frame
Incidence of CRBD;

Secondary

MeasureTime frame
Quality of Life QoR15;Sleep quality;Incidence of delirium;Incidence of CRBD by grade at each time point;Pain;

Countries

China

Contacts

Public ContactYu Wenli

Tianjin First Central Hospital

yzxyuwenli@163.com+86 22 23627130

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Sep 19, 2026